Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Schizophrenia Clinical Trials

109 recruiting trials for Schizophrenia. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
109
Total Trials
109
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT05635266

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and...

Sponsor: Sanguine BiosciencesEnrolling: 200001 location
RECRUITINGNCT04610697

Cognitive Remediation in Forensic Mental Health Care

Forensic patients often display cognitive deficits, particularly in the domain of executive functions, that represent a challenge to forensic rehabilitation. One...

Sponsor: The Royal Ottawa Mental Health CentreEnrolling: 301 location
RECRUITINGNCT04296604

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

In the current study, the investigators aim to understand the role of transcranial direct current stimulation (tDCS) in improving executive function across neuropsychiatric...

Sponsor: Massachusetts General HospitalEnrolling: 6001 location
RECRUITINGNCT06890208

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave

The CLIMATE-III Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific health...

Sponsor: Universitätsklinikum Hamburg-EppendorfEnrolling: 2401 location
RECRUITINGNCT06657430

A Study on the Preference of Risperidone Dosage Forms

This study aimed to understand patients' needs and preferences for antipsychotic dosage forms.

Sponsor: Shanghai Mental Health CenterEnrolling: 10001 location
RECRUITINGPhase 4NCT04580134

CLOZAPINE Response in Biotype-1

The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The...

Sponsor: University of Texas Southwestern Medical CenterEnrolling: 5245 locations
RECRUITINGNCT04432116

Time and Virtual Reality in Schizophrenia and Bipolar Disorder

Patients with bipolar disorders report an acceleration or slowing of time flow, and patients with schizophrenic spectrum disorders a time fragmentation. These disorders would be...

Sponsor: Institut National de la Santé Et de la Recherche Médicale, FranceEnrolling: 1201 location
RECRUITINGNCT06182787

Development of a Model for Digital Monitoring of the Mental State of the Hospitalized Patient

This study presents the development and validation of a unique Digital Experience Sampling Method (ESM) questionnaire specifically adapted for monitoring changes in the mental...

Sponsor: Sheba Medical CenterEnrolling: 1301 location
RECRUITINGNCT06071858

Enhanced Coordinated Specialty Care for Early Psychosis

The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The...

Sponsor: Mclean HospitalEnrolling: 3505 locations
RECRUITINGPhase 4NCT05648591

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

Sponsor: Vanda PharmaceuticalsEnrolling: 1009 locations
RECRUITINGNCT05866107

App and Body Fat Scale in the Management of Overweight Patients

This study tests whether using a health app (Huawei Health) and a smart body fat scale can help overweight patients with schizophrenia or bipolar disorder lose weight and stay...

Sponsor: Capital Medical UniversityEnrolling: 2041 location
RECRUITINGNCT06107764

Cerebellar Modulation of Cognition in Psychosis

The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to...

Sponsor: Mclean HospitalEnrolling: 952 locations
RECRUITINGNCT04946916

Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease

The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate...

Sponsor: Hôpital le VinatierEnrolling: 1202 locations
RECRUITINGPhase 3NCT06229210

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism...

This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism...

Sponsor: Intra-Cellular Therapies, Inc.Enrolling: 50020 locations
RECRUITINGNCT07479758

Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment...

This is an observational study aiming to screen biomarkers associated with the diagnosis and treatment outcomes of severe mental disorders (MDD/major depressive disorder,...

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityEnrolling: 3201 location
RECRUITINGNCT05491538

Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness

Many individuals with serious mental illness have difficulty accurately interpreting interpersonal cues and effectively engaging in social exchanges. Difficulties related to the...

Sponsor: VA Office of Research and DevelopmentEnrolling: 201 location
RECRUITINGPhase 1NCT05025605

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

Sponsor: BioXcel Therapeutics IncEnrolling: 1405 locations
RECRUITINGNCT06197048

Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or...

The goal of this clinical trial is to compare the effect of nutritional counseling versus no treatment in patients with schizophenia or bipolar affective disorder. The main...

Sponsor: Vestre Viken Hospital TrustEnrolling: 402 locations
RECRUITINGPhase 1 / Phase 2NCT07185815

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine...

The purpose of this study is to assess the PK, Safety, Tolerability (all cohorts) and Efficacy (cohort 3), of once-a-month long-acting SC injection of dose escalating Cariprazine...

Sponsor: Mapi Pharma Ltd.Enrolling: 243 locations
RECRUITINGNCT07176468

Personalized iTBS in Real-World Clinical Settings for Schizophrenia

This study is designed to determine whether neuronavigation-guided, personalized Intermittent Theta-Burst Stimulation (iTBS) can produce clinically benefits for patients with...

Sponsor: Anhui Medical UniversityEnrolling: 402 locations
RECRUITINGNCT04278339

Study of Electrophysiological Markers Related to the Cognitive and Affective Processes Behind Empathic Behaviour in...

Disorders of social cognition, and empathy more specifically, are at the heart of schizophrenic pathology in that they are strongly linked to the social handicap of patients. It...

Sponsor: Centre Hospitalier Universitaire de NiceEnrolling: 701 location
RECRUITINGNCT04945278

Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability

The main objective of this study is to establish whether there are differences in self-recognition and self/other distinction in subjects with psychological vulnerability compared...

Sponsor: University Hospital, BrestEnrolling: 341 location
RECRUITINGNCT05440214

Targeting Emotion Dysregulation to Reduce Suicide in People With Psychosis

People with psychotic disorders are excluded from most suicide-focused clinical trials despite incredibly high rates of completed suicide, and interventions that have been tested...

Sponsor: University of Maryland, BaltimoreEnrolling: 681 location
RECRUITINGPhase 3NCT07424404

A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and...

The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in...

Sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb companyEnrolling: 40020 locations
RECRUITINGNCT06650943

Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP)

The goal of this clinical trial is to evaluate if a nursing intervention based on the carbohydrate-insulin model can effectively reduce weight and manage the risk of metabolic...

Sponsor: Hospital de BasurtoEnrolling: 881 location
RECRUITINGNCT06888726

Efficacy of Hi-tACS for Schizophrenia Negative Symptoms

The goal of this clinical trial is to investigate whether Hi-tACS is effective and safe in treating negative symptoms of schizophrenia. Schizophrenic patients will receive...

Sponsor: Shanghai Mental Health CenterEnrolling: 601 location
RECRUITINGNCT06410508

Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis

Negative experiences with healthcare prior to referral to early intervention services for psychosis (EIS) have been linked to poor engagement and clinical outcomes. Recent...

Sponsor: Nova Scotia Health AuthorityEnrolling: 401 location
RECRUITINGPhase 4NCT02639702

Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia

Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics; for example, it is recommended that agents with a short plasma half-life be...

Sponsor: Centre for Addiction and Mental HealthEnrolling: 301 location
RECRUITINGNCT06781801

Improving Heart and Metabolic Health in People With Severe Mental Illness Through a Long-term Clinical Trial

Cardiometabolic diseases are prevalent among individuals with psychotic disorders, significantly contributing to their shorter lifespan, reduced quality of life, and economic...

Sponsor: Vastra Gotaland RegionEnrolling: 6446 locations
RECRUITINGNCT06556251

Effectiveness of a Digital Platform in Engagement and Prognosis of Patients in an Early Intervention Pychosis Programme

This is a randomised, prospective, controlled trial in which one group (experimental group; GE) receives access to the PIPPEP (Intervention Programme for Early Psychosis) platform...

Sponsor: Fundació Sant Joan de DéuEnrolling: 1281 location
RECRUITINGNCT06729541

Development and Application of Precision Treatment Strategies for Common Mental Disorders

Schizophrenia (SCH), major depressive disorder (MDD), and bipolar disorder (BPD) are prevalent, disabling psychiatric conditions that not only cause significant suffering for...

Sponsor: Peking UniversityEnrolling: 6001 location
RECRUITINGNCT07360665

Multimodal Physical Exercise Program (Physical Exercise for Psychosis) for People With Psychosis Treated With...

People with psychotic disorders, such as schizophrenia, often experience significant difficulties in daily functioning, physical health, and quality of life. Long-acting...

Sponsor: University of Trás-os-Montes and Alto DouroEnrolling: 441 location
RECRUITINGNCT06573320

Effect of Exercise on Clinical Symptoms, Cognitive Performance, and Quality of Life in Schizophrenia Patients Treated...

This prospective study aims to investigate the effects of exercise on clinical symptoms, cognitive performance, and quality of life in schizophrenia patients treated with...

Sponsor: Dr. Lutfi Kirdar Kartal Training and Research HospitalEnrolling: 601 location
RECRUITINGPhase 2 / Phase 3NCT03094429

An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of...

This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as...

Sponsor: SyneuRx International (Taiwan) CorpEnrolling: 2871 location
RECRUITINGPhase 3NCT06894212

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.Enrolling: 52220 locations
RECRUITINGNCT07343193

Deprescribing Antipsychotics: a Multiple Case Study

The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations...

Sponsor: University Hospital, Strasbourg, FranceEnrolling: 301 location
RECRUITINGNCT07306468

Effects of Schizophrenia and Bipolar Disorder on Exercise Capacity, Pulmonary Function, and Quality of Life

This observational study aims to evaluate exercise capacity, pulmonary function, respiratory muscle strength, and quality of life in individuals diagnosed with schizophrenia and...

Sponsor: Çankırı Karatekin UniversityEnrolling: 1501 location
RECRUITINGPhase 2NCT07038876

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

ML-007C-MA-211 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered ML-007C-MA in inpatient...

Sponsor: MapLight TherapeuticsEnrolling: 30020 locations
RECRUITINGNCT06484387

Study of Intra- and Interpersonal Multimodal Synchronizations in a Social Interaction in Individuals with a Diagnosis...

The aim of this study is to precisely identify deficits in intra- and interpersonal multimodal synchronizations during social interaction in individuals with schizophrenia (ISZ)....

Sponsor: University Hospital, MontpellierEnrolling: 1201 location
RECRUITINGNCT06802939

RTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography

This study is an before-after study in the same patient, which enrolled 36 psychiatric patients with refractory auditory hallucinations. The target of patient intervention relies...

Sponsor: Shanghai Mental Health CenterEnrolling: 361 location
RECRUITINGNCT04300946

Time Prediction and Cerebellum: Magnetic Transcranial Stimulation (TMS) in Healthy Volunteers

The aim of the study is to check the role of the cerebellum in time prediction in healthy volunteers, by means of magnetic transcranial stimulation targeted on the cerebellum, and...

Sponsor: University Hospital, Strasbourg, FranceEnrolling: 481 location
RECRUITINGNCT02455193

Neuronal Effects of Exercise in Schizophrenia

This study plans to learn more about how common drugs prescribed to individuals with schizophrenia contribute to weight gain, as well as how exercise and diet impact appetite and...

Sponsor: University of Colorado, DenverEnrolling: 1401 location
RECRUITINGNCT07213492

Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder

People with bipolar disorder (BD) are at high risk of relapse following hospital discharge, partly due to a lack of BD-specific expertise and resources within community services...

Sponsor: McMaster UniversityEnrolling: 101 location
RECRUITINGNCT06138054

MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI

This study aims to test the feasibility and acceptability of a brief behavioral intervention that combines two treatments, Motivational Interviewing (MI) and Cognitive Behavioral...

Sponsor: VA Office of Research and DevelopmentEnrolling: 501 location
RECRUITINGNCT06581302

Magnetic Seizure Therapy for Psychotic Disorders

This trial aims to evaluate the efficacy and safety of Magnetic Seizure Therapy (MST) as an augmentation of antipsychotic medications for psychosis.

Sponsor: Shanghai Jiao Tong University School of MedicineEnrolling: 502 locations
RECRUITINGNCT03525054

Semantic and Syntactic Computerized Analysis of Free Speech

Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify...

Sponsor: University Hospital, BrestEnrolling: 1503 locations
RECRUITINGPhase 4NCT06634641

Clozapine-related Immunodeficiency in Parkinsons Disease

Clozapine is a second generation antipsychotic drug used in psychiatry to treat schizophrenia, affective disorders or certain symptoms of dementia. In neurology, clozapine is...

Sponsor: Centre Hospitalier Universitaire, AmiensEnrolling: 241 location
RECRUITINGNCT06856161

A Novel Blood Test as a Biomarker in Mental Health

This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in...

Sponsor: Fraser HealthEnrolling: 5001 location
RECRUITINGNCT07060066

Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia

The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia....

Sponsor: The University of Texas Health Science Center, HoustonEnrolling: 1201 location
RECRUITINGNCT04730518

Yoga-based Group Intervention (YoGI) for In-patients With Schizophrenia Spectrum Disorders

A rater-blinded randomized controlled trial with a parallel-group design is utilized, comprised of yoga-based group intervention (YoGI) in the experimental condition, and...

Sponsor: Charite University, Berlin, GermanyEnrolling: 771 location

Showing 50 of 109 trials.Search all Schizophrenia trials

Frequently Asked Questions

There are currently 109 clinical trials for Schizophrenia, with 109 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Schizophrenia, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Schizophrenia, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.